Ballicules.com
Withdrawn from the market (business decision)

Lesinurad

ZURAMPIC

Pronunciation: le-SIN-yoor-ad (zer-AM-pik)

Lesinurad ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Lesinurad ballicule

What it isURAT1 (and OAT4) inhibitor that increases renal uric acid excretion (uricosuric).

Why this oneAdd-on to a xanthine oxidase inhibitor for gout patients not reaching target serum urate on the XOI alone.

What limits itMust be taken with a xanthine oxidase inhibitor and adequate hydration because of renal risk, and it was withdrawn from the market in 2019.

Lesinurad molecular structure (skeletal formula)
Molecular structure: Lesinurad

⚠ BOXED WARNING

Principal riskBoxed warning: risk of acute renal failure, more common when used without a xanthine oxidase inhibitor.

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger1 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Open Lesinurad in the interactive console ↗